BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10088822)

  • 1. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change.
    Grierson I; Lee WR; Albert DM
    Arch Ophthalmol; 1999 Mar; 117(3):394-6. PubMed ID: 10088822
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence of early change in iris color with latanoprost use.
    Pappas RM; Pusin S; Higginbotham EJ
    Arch Ophthalmol; 1998 Aug; 116(8):1115-6. PubMed ID: 9715697
    [No Abstract]   [Full Text] [Related]  

  • 3. Iris morphology.
    Teus MA; Arranz-Marquez E
    Ophthalmology; 2008 Feb; 115(2):418-9; author reply 419-20. PubMed ID: 18243921
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased iris pigment in a child due to latanoprost.
    Brown SM
    Arch Ophthalmol; 1998 Dec; 116(12):1683-4. PubMed ID: 9869807
    [No Abstract]   [Full Text] [Related]  

  • 5. Histology and fine structure of the iris and outflow system following latanoprost therapy.
    Grierson I; Pfeiffer N; Cracknell KP; Appleton P
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphometric effects of long-term exposure to latanoprost.
    Cracknell KP; Grierson I; Hogg P
    Ophthalmology; 2007 May; 114(5):938-48. PubMed ID: 17292473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latanoprost-induced iris color darkening: a case report with long-term follow-up.
    Camras CB; Neely DG; Weiss EL
    J Glaucoma; 2000 Feb; 9(1):95-8. PubMed ID: 10708238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.
    Wistrand PJ; Stjernschantz J; Olsson K
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S129-38. PubMed ID: 9154289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin-induced iridial pigmentation in primates.
    Selén G; Stjernschantz J; Resul B
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S125-8. PubMed ID: 9154288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation.
    Imesch PD; Wallow IH; Albert DM
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S117-23. PubMed ID: 9154287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study.
    Chiba T; Kashiwagi K; Chiba N; Ishijima K; Furuichi M; Kogure S; Abe K; Tsukahara S
    Br J Ophthalmol; 2003 Aug; 87(8):956-9. PubMed ID: 12881333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.
    Chiba T; Kashiwagi K; Kogure S; Abe K; Shibuya T; Furuichi M; Iijima H; Tsukahara S
    J Glaucoma; 2001 Oct; 10(5):406-10. PubMed ID: 11711839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism and clinical significance of prostaglandin-induced iris pigmentation.
    Stjernschantz JW; Albert DM; Hu DN; Drago F; Wistrand PJ
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S162-75. PubMed ID: 12204714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
    Tsai JC; Sivak-Callcott JA; Haik BG; Zhang J; McLean IW
    J Glaucoma; 2001 Oct; 10(5):411-3. PubMed ID: 11711840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iris cyst associated with topical administration of latanoprost.
    Krohn J; Hove VK
    Am J Ophthalmol; 1999 Jan; 127(1):91-3. PubMed ID: 9933009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension.
    Alm A; Grunden JW; Kwok KK
    J Glaucoma; 2011; 20(4):215-22. PubMed ID: 20520568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group.
    Camras CB; Wax MB; Ritch R; Weinreb R; Robin AL; Higginbotham EJ; Lustgarten J; Stewart WC; Sherwood M; Krupin T; Wilensky J; Cioffi GA; Katz LJ; Schumer RA; Kaufman PL; Minckler D; Zimmerman T; Stjernschantz J
    Am J Ophthalmol; 1998 Sep; 126(3):390-9. PubMed ID: 9744372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Increased iris pigmentation after use of latanoprost in Japanese brown eyes].
    Hara T
    Nippon Ganka Gakkai Zasshi; 2001 May; 105(5):314-21. PubMed ID: 11406947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes.
    Latanoprost-Induced Iris Pigmentation Study Group
    Jpn J Ophthalmol; 2006; 50(2):96-9. PubMed ID: 16604382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.